Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 va...

Full description

Saved in:
Bibliographic Details
Published inEmerging microbes & infections Vol. 10; no. 1; pp. 629 - 637
Main Authors He, Qian, Mao, Qunying, An, Chaoqiang, Zhang, Jialu, Gao, Fan, Bian, Lianlian, Li, Changgui, Liang, Zhenglun, Xu, Miao, Wang, Junzhi
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 2021
Taylor & Francis Ltd
Taylor & Francis Group
Subjects
Adenovirus Vaccines - administration & dosage
Adenovirus Vaccines - immunology
Adenoviruses
Animals
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Clinical trials
COVID-19 - prevention & control
COVID-19 vaccine
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
COVID-19 Vaccines - immunology
Drug dosages
Food
Heterologous prime-boost
Immune response
Immunization, Secondary - methods
Interferon-gamma - blood
Lymphocyte Count
Lymphocytes
Mice
Mice, Inbred BALB C
mRNA Vaccines
neutralizing antibody
Pandemics
Peptides
Proteins
Public health
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
T cell response
T-Lymphocytes - immunology
T-Lymphocytes, Helper-Inducer - immunology
th1/th2 balance
Vaccination - adverse effects
Vaccines, Subunit - administration & dosage
Vaccines, Subunit - immunology
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Variance analysis
COVID-19 vaccine
neutralizing antibody
th1/th2 balance
Heterologous prime-boost
T cell response
Online AccessGet full text

Cover

Abstract COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic.
AbstractList COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic.
COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic.COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we explored the utility of employing a heterologous prime-boost strategy in which different combinations of the four types of leading COVID-19 vaccine candidates that are undergoing clinical trials in China were tested in a mouse model. Our results showed that sequential immunization with adenovirus vectored vaccine followed by inactivated/recombinant subunit/mRNA vaccine administration specifically increased levels of neutralizing antibodies and promoted the modulation of antibody responses to predominantly neutralizing antibodies. Moreover, a heterologous prime-boost regimen with an adenovirus vector vaccine also improved Th1-biased T cell responses. Our results provide new ideas for the development and application of COVID-19 vaccines to control the SARS-CoV-2 pandemic.
Author Li, Changgui
Liang, Zhenglun
Xu, Miao
An, Chaoqiang
Bian, Lianlian
Mao, Qunying
Zhang, Jialu
Wang, Junzhi
He, Qian
Gao, Fan
Author_xml – sequence: 1
  givenname: Qian
  surname: He
  fullname: He, Qian
  organization: National Institutes for Food and Drug Control
– sequence: 2
  givenname: Qunying
  surname: Mao
  fullname: Mao, Qunying
  organization: National Institutes for Food and Drug Control
– sequence: 3
  givenname: Chaoqiang
  surname: An
  fullname: An, Chaoqiang
  organization: National Institutes for Food and Drug Control
– sequence: 4
  givenname: Jialu
  surname: Zhang
  fullname: Zhang, Jialu
  organization: National Institutes for Food and Drug Control
– sequence: 5
  givenname: Fan
  surname: Gao
  fullname: Gao, Fan
  organization: National Institutes for Food and Drug Control
– sequence: 6
  givenname: Lianlian
  surname: Bian
  fullname: Bian, Lianlian
  organization: National Institutes for Food and Drug Control
– sequence: 7
  givenname: Changgui
  surname: Li
  fullname: Li, Changgui
  organization: National Institutes for Food and Drug Control
– sequence: 8
  givenname: Zhenglun
  surname: Liang
  fullname: Liang, Zhenglun
  email: lzhenglun@126.com
  organization: National Institutes for Food and Drug Control
– sequence: 9
  givenname: Miao
  surname: Xu
  fullname: Xu, Miao
  email: xumiaobj@126.com
  organization: National Institutes for Food and Drug Control
– sequence: 10
  givenname: Junzhi
  surname: Wang
  fullname: Wang, Junzhi
  email: wangjz@nifdc.org.cn
  organization: National Institutes for Food and Drug Control
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33691606$$D View this record in MEDLINE/PubMed
BookMark eNqFUk1v1DAQjVAR_aA_ARSJC5cs_kicBCQEWj66UqVegKs1diZb7yb2YnsX9d_XYbdV2wPMxdbMm6d5M-80O7LOYpa9omRGSUPesRS0ruiMEUZntCWMldWz7GTKF1Ph6MH_ODsPYUVS1ESUtHyRHXMuWiqIOMnWFxjRu8Et3TbkG29GLJRzIb7PlUdYG7vM4zWmiouoo9lhbsZxazH3GDbOBsyVi3FAi3qduz6fX_1afClom-9Aa5NwGmxnOogYXmbPexgCnh_es-znt68_5hfF5dX3xfzzZaHLuq6Kjqu6rARUWihOKRFckKrsqE7KNVAEYC0XouKYRHc9ENX2tOGKEaCKMsLPssWet3OwkpMm8DfSgZF_E84vJfho9ICSlFBWLa1ESfpSC6pA6ZoTQWsQAmuRuD7uuTZbNWKn0UYPwyPSxxVrruXS7WRDSEsZSwRvDwTe_d5iiHI0QeMwgMW0cskqQnidYpr7zRPoym29TauSPN24ZE3dNAn1-uFE96Pc3TQBqj1AexeCx_4eQomc7CPv7CMn-8iDfVLfhyd92kSIxk3CzPDf7k_7bmN750f44_zQyQg3g_O9B6vNpOKfFLdiHdt3
CitedBy_id crossref_primary_10_1080_08923973_2022_2037631
crossref_primary_10_1002_hsr2_70089
crossref_primary_10_31631_2073_3046_2024_23_2_94_101
crossref_primary_10_3389_fgene_2023_1157305
crossref_primary_10_1016_j_banm_2021_09_010
crossref_primary_10_1186_s12985_021_01737_3
crossref_primary_10_1016_j_lfs_2021_119901
crossref_primary_10_1080_22221751_2021_2021807
crossref_primary_10_12991_jrespharm_1626413
crossref_primary_10_3390_vaccines11050963
crossref_primary_10_3389_fimmu_2022_864718
crossref_primary_10_3390_ijms25021076
crossref_primary_10_1002_mco2_188
crossref_primary_10_3390_biomedicines9091163
crossref_primary_10_3390_vaccines10040491
crossref_primary_10_1186_s13005_021_00289_9
crossref_primary_10_1038_s41467_021_27063_4
crossref_primary_10_1080_22221751_2021_1951624
crossref_primary_10_3390_vaccines10010062
crossref_primary_10_1038_s41541_021_00394_5
crossref_primary_10_1007_s12038_023_00355_1
crossref_primary_10_1016_j_vaccine_2021_11_083
crossref_primary_10_3390_ijms25010215
crossref_primary_10_1016_j_biopha_2022_112650
crossref_primary_10_3390_vaccines10040536
crossref_primary_10_1186_s12916_021_02231_x
crossref_primary_10_3390_vaccines10060845
crossref_primary_10_1016_S2213_2600_21_00366_0
crossref_primary_10_3390_v13101911
crossref_primary_10_1093_cid_ciac796
crossref_primary_10_3389_fimmu_2022_1020159
crossref_primary_10_5326_JAAHA_MS_7468
crossref_primary_10_1515_mr_2021_0021
crossref_primary_10_1080_21645515_2021_2007015
crossref_primary_10_3389_fmed_2022_924454
crossref_primary_10_1001_jamainternmed_2021_7372
crossref_primary_10_1002_jmv_29454
crossref_primary_10_3390_v14091854
crossref_primary_10_3390_vaccines10020322
crossref_primary_10_3390_vaccines10050639
crossref_primary_10_1111_irv_13290
crossref_primary_10_1111_eci_14296
crossref_primary_10_1016_j_heliyon_2024_e25733
crossref_primary_10_1080_22221751_2023_2191738
crossref_primary_10_1097_ID9_0000000000000027
crossref_primary_10_3390_vaccines11081329
crossref_primary_10_3389_fimmu_2024_1460442
crossref_primary_10_1038_s41467_024_50087_5
crossref_primary_10_3390_vaccines10020160
crossref_primary_10_47093_2713_069X_2021_2_1_5_11
crossref_primary_10_1016_j_jtct_2021_09_016
crossref_primary_10_3390_v16030418
crossref_primary_10_3390_vaccines10050788
crossref_primary_10_1016_S0140_6736_21_01694_9
crossref_primary_10_2147_IJN_S464720
crossref_primary_10_3390_vaccines11040715
crossref_primary_10_3389_fimmu_2022_949248
crossref_primary_10_3389_fpubh_2023_1253762
crossref_primary_10_3389_fimmu_2024_1406138
crossref_primary_10_3390_vaccines10071080
crossref_primary_10_3390_vaccines10122126
crossref_primary_10_1080_21645515_2022_2057161
crossref_primary_10_1371_journal_ppat_1011744
crossref_primary_10_1186_s13063_022_06345_2
crossref_primary_10_3390_pathogens12050655
crossref_primary_10_1093_jtm_taab191
crossref_primary_10_1016_j_jff_2024_106561
crossref_primary_10_1016_j_msard_2022_104009
crossref_primary_10_3390_idr14040057
crossref_primary_10_1080_22221751_2021_1957401
crossref_primary_10_1111_joim_13551
crossref_primary_10_3390_vaccines12020120
crossref_primary_10_1016_j_omtm_2023_03_010
crossref_primary_10_3390_vaccines9101052
crossref_primary_10_1016_j_jinf_2023_10_012
crossref_primary_10_3390_vaccines12080927
crossref_primary_10_3390_vaccines10030414
crossref_primary_10_2139_ssrn_4133614
crossref_primary_10_3390_v15051099
crossref_primary_10_3390_vaccines13040338
crossref_primary_10_3390_bioengineering10020148
crossref_primary_10_1016_S1473_3099_23_00199_8
crossref_primary_10_1038_s41541_022_00568_9
crossref_primary_10_3389_fimmu_2023_1129118
crossref_primary_10_1080_14760584_2023_2242528
crossref_primary_10_1016_j_vaccine_2022_02_019
crossref_primary_10_3389_fmed_2022_936126
crossref_primary_10_3390_vaccines9080918
crossref_primary_10_1056_NEJMoa2116747
crossref_primary_10_1080_22221751_2021_1942227
crossref_primary_10_3390_vaccines9101186
crossref_primary_10_1016_j_isci_2021_103694
crossref_primary_10_5326_JAAHA_MS_Canine_Vaccination_Guidelines
crossref_primary_10_1016_j_vetmic_2023_109799
crossref_primary_10_1038_s41598_022_16445_3
crossref_primary_10_3389_fimmu_2022_883612
crossref_primary_10_3389_fimmu_2021_753319
crossref_primary_10_3390_vaccines11030537
crossref_primary_10_1016_j_ijmmb_2021_08_001
crossref_primary_10_3390_vaccines9111261
crossref_primary_10_1002_jmv_27637
crossref_primary_10_1038_s41392_022_00979_z
crossref_primary_10_3389_fpubh_2023_1165611
crossref_primary_10_3390_vaccines10030392
crossref_primary_10_1080_22221751_2022_2143283
crossref_primary_10_2144_fsoa_2023_0090
crossref_primary_10_1016_j_ymthe_2022_04_016
crossref_primary_10_3390_vaccines9070733
crossref_primary_10_1038_s41591_021_01677_z
crossref_primary_10_1080_22221751_2022_2152388
crossref_primary_10_1186_s12985_022_01818_x
crossref_primary_10_1371_journal_pmed_1003991
Cites_doi 10.1001/jama.2020.15543
10.1080/14760584.2019.1640117
10.1016/S0140-6736(20)31605-6
10.4161/hv.28659
10.1056/NEJMoa2026920
10.1038/s41467-020-18450-4
10.1016/S0140-6736(20)31866-3
10.1056/NEJMoa2022483
10.1016/S1473-3099(20)30831-8
10.1080/22221751.2020.1743767
10.1038/s41586-020-03041-6
10.1038/s41564-020-00789-5
10.1056/NEJMoa2027906
10.1056/NEJMoa2034577
10.1016/j.coi.2009.05.016
10.1056/NEJMoa2029849
10.4161/hv.25750
10.1016/j.vaccine.2008.04.073
10.1056/NEJMoa2035389
10.3390/ijms21228524
10.1016/S1473-3099(20)30843-4
10.1128/JVI.79.12.7933-7937.2005
10.1016/S0140-6736(20)32466-1
10.1016/j.cell.2015.07.005
10.1016/j.chom.2020.08.002
10.1056/NEJMc2032195
10.1016/S0140-6736(20)32661-1
ContentType Journal Article
Copyright 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021
2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 The Author(s)
Copyright_xml – notice: 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021
– notice: 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2021 The Author(s)
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1080/22221751.2021.1902245
DatabaseName Taylor & Francis Open Access Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic



MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
– sequence: 5
  dbid: BENPR
  name: ProQuest Central (NC Live)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
DocumentTitleAlternate Emerging Microbes & Infections
EISSN 2222-1751
EndPage 637
ExternalDocumentID oai_doaj_org_article_04a45915640f4c61babc730617a66e76
PMC8009122
33691606
10_1080_22221751_2021_1902245
1902245
Genre Research Article
Journal Article
GrantInformation_xml – fundername: Ministry of Science and Technology of the People's Republic of China
  grantid: 2020YFC0860500
  funderid: 10.13039/501100002855
GroupedDBID 0YH
3V.
53G
5VS
7X7
8FI
AAHBH
ACGFS
ADBBV
ADRAZ
AENEX
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BENPR
BPHCQ
BVXVI
C6C
DIK
EBS
ECGQY
EMOBN
FYUFA
GROUPED_DOAJ
HYE
KQ8
M1P
M48
M4Z
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
RNT
RNTTT
RPM
TDBHL
UKHRP
88E
8FJ
AAYXX
ABUWG
BCNDV
CCPQU
CITATION
EJD
HMCUK
PHGZM
PHGZT
PSQYO
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c4775-d3b7456a5c6b3110636054d1c080ca1eaa2936653e245dfa0b9f183b20a1b1203
IEDL.DBID M48
ISSN 2222-1751
IngestDate Wed Aug 27 01:30:07 EDT 2025
Thu Aug 21 13:32:14 EDT 2025
Fri Jul 11 06:53:41 EDT 2025
Fri Jul 25 10:23:00 EDT 2025
Thu Apr 03 07:05:51 EDT 2025
Thu Apr 24 22:55:09 EDT 2025
Tue Jul 01 04:46:46 EDT 2025
Wed Dec 25 09:06:04 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords COVID-19 vaccine
neutralizing antibody
th1/th2 balance
Heterologous prime-boost
T cell response
Language English
License open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4775-d3b7456a5c6b3110636054d1c080ca1eaa2936653e245dfa0b9f183b20a1b1203
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Contributed equally to this work.
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1080/22221751.2021.1902245
PMID 33691606
PQID 3190428788
PQPubID 2041957
PageCount 9
ParticipantIDs proquest_journals_3190428788
pubmed_primary_33691606
crossref_primary_10_1080_22221751_2021_1902245
doaj_primary_oai_doaj_org_article_04a45915640f4c61babc730617a66e76
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8009122
informaworld_taylorfrancis_310_1080_22221751_2021_1902245
proquest_miscellaneous_2500377770
crossref_citationtrail_10_1080_22221751_2021_1902245
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-00-00
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – year: 2021
  text: 2021-00-00
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: London
PublicationTitle Emerging microbes & infections
PublicationTitleAlternate Emerg Microbes Infect
PublicationYear 2021
Publisher Taylor & Francis
Taylor & Francis Ltd
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Ltd
– name: Taylor & Francis Group
References e_1_3_6_30_1
e_1_3_6_32_1
e_1_3_6_33_1
e_1_3_6_11_1
e_1_3_6_10_1
Qi H (e_1_3_6_31_1) 2014; 841
Yang S (e_1_3_6_14_1) 2020; 396
e_1_3_6_15_1
e_1_3_6_13_1
e_1_3_6_12_1
e_1_3_6_19_1
e_1_3_6_18_1
e_1_3_6_17_1
e_1_3_6_16_1
e_1_3_6_20_1
e_1_3_6_21_1
e_1_3_6_22_1
e_1_3_6_2_1
e_1_3_6_5_1
e_1_3_6_4_1
e_1_3_6_3_1
e_1_3_6_9_1
e_1_3_6_8_1
e_1_3_6_7_1
e_1_3_6_27_1
e_1_3_6_28_1
e_1_3_6_29_1
e_1_3_6_23_1
e_1_3_6_24_1
e_1_3_6_25_1
Davies NG (e_1_3_6_6_1) 2020
e_1_3_6_26_1
References_xml – year: 2020
  ident: e_1_3_6_6_1
  article-title: Estimated transmissibility and severity of novel SARS-CoV-2 Variant of concern 202012/01 in england
  publication-title: MedRxiv
– volume: 396
  start-page: 479
  year: 2020
  ident: e_1_3_6_14_1
  article-title: Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials
  publication-title: medRxiv
– ident: e_1_3_6_10_1
  doi: 10.1001/jama.2020.15543
– ident: e_1_3_6_17_1
  doi: 10.1080/14760584.2019.1640117
– ident: e_1_3_6_15_1
  doi: 10.1016/S0140-6736(20)31605-6
– ident: e_1_3_6_30_1
  doi: 10.4161/hv.28659
– ident: e_1_3_6_11_1
  doi: 10.1056/NEJMoa2026920
– ident: e_1_3_6_24_1
  doi: 10.1038/s41467-020-18450-4
– ident: e_1_3_6_29_1
  doi: 10.1016/S0140-6736(20)31866-3
– ident: e_1_3_6_4_1
  doi: 10.1056/NEJMoa2022483
– ident: e_1_3_6_5_1
– ident: e_1_3_6_9_1
  doi: 10.1016/S1473-3099(20)30831-8
– ident: e_1_3_6_19_1
  doi: 10.1080/22221751.2020.1743767
– ident: e_1_3_6_20_1
  doi: 10.1038/s41586-020-03041-6
– ident: e_1_3_6_28_1
  doi: 10.1038/s41564-020-00789-5
– ident: e_1_3_6_26_1
  doi: 10.1056/NEJMoa2027906
– ident: e_1_3_6_2_1
  doi: 10.1056/NEJMoa2034577
– ident: e_1_3_6_18_1
  doi: 10.1016/j.coi.2009.05.016
– ident: e_1_3_6_23_1
  doi: 10.1056/NEJMoa2029849
– ident: e_1_3_6_22_1
  doi: 10.4161/hv.25750
– ident: e_1_3_6_21_1
  doi: 10.1016/j.vaccine.2008.04.073
– ident: e_1_3_6_25_1
  doi: 10.1056/NEJMoa2035389
– ident: e_1_3_6_32_1
  doi: 10.3390/ijms21228524
– ident: e_1_3_6_12_1
  doi: 10.1016/S1473-3099(20)30843-4
– ident: e_1_3_6_33_1
  doi: 10.1128/JVI.79.12.7933-7937.2005
– ident: e_1_3_6_8_1
  doi: 10.1016/S0140-6736(20)32466-1
– ident: e_1_3_6_27_1
  doi: 10.1016/j.cell.2015.07.005
– ident: e_1_3_6_16_1
  doi: 10.1016/j.chom.2020.08.002
– ident: e_1_3_6_13_1
  doi: 10.1016/S1473-3099(20)30831-8
– volume: 841
  start-page: 15380
  year: 2014
  ident: e_1_3_6_31_1
  article-title: Tfh cell differentiation and their function in promoting B-cell responses
  publication-title: Adv Exp Med Biol
– ident: e_1_3_6_7_1
  doi: 10.1056/NEJMc2032195
– ident: e_1_3_6_3_1
  doi: 10.1016/S0140-6736(20)32661-1
SSID ssj0000706414
Score 2.5445623
Snippet COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 629
SubjectTerms Adenovirus Vaccines - administration & dosage
Adenovirus Vaccines - immunology
Adenoviruses
Animals
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Clinical trials
COVID-19 - prevention & control
COVID-19 vaccine
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
COVID-19 Vaccines - immunology
Drug dosages
Food
Heterologous prime-boost
Immune response
Immunization, Secondary - methods
Interferon-gamma - blood
Lymphocyte Count
Lymphocytes
Mice
Mice, Inbred BALB C
mRNA Vaccines
neutralizing antibody
Pandemics
Peptides
Proteins
Public health
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
T cell response
T-Lymphocytes - immunology
T-Lymphocytes, Helper-Inducer - immunology
th1/th2 balance
Vaccination - adverse effects
Vaccines, Subunit - administration & dosage
Vaccines, Subunit - immunology
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Variance analysis
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELUqTpUqREspaQG5Uq8BO_FH0lv50lKp5QKImzV2HIFAAcG2v78zdna1iyrthT1uYin2TOa9cTxvGPsmO6ThtoeyMUGXSkdZtg2gQWLTA8m7qIpqh3_9NpNL9fNaXy-0-qIzYVkeOC_cgVCgdEuSJqJXwUgPPqBXIvCCMdEmsW3EvIVkKsVgi1Ar1axkpxEHiIPIvjWlhJXcRxhE7NJLYJQ0-18olv6Pd748PrmAR6cbbH0kkvxHnsB79iYOH9i7vAvHc3HRJrub0GkXim-Y4PNHkvIvkVY_T79zTIVTIyqODJCPag0Y-fgtFYxE_pTPzkZOrcYQmWK44w89Pzq_OjsuZcv_QqBP8jxQWQztGjx_ZJenJxdHk3Jsr1AGZa0uu9pbpE-gg_FoFEHKYVp1krTHA8gIgFTAGF1HXKmuB-HbHgOArwRILytRb7G14WGI24x3SDyg6YLoW8xnOgOkVGYhoIWk70JdMDVbZxdG7XFqgXHv5ChROjOPI_O40TwF258Pe8ziG6sGHJIR5zeTdnb6Az3KjR7lVnlUwdpFF3DTtHXS5z4nrl7xADszf3FjMKAhbcpMm6ZgX-eX8TWmbzMwRPQAh0xU1BZ_omCfsnvNZ1HXBkm8wAezS463NM3lK8PtTZIKx3SglVX1-TXW5Qt7S1PN-087bG369CfuIiOb-r308v0DdhYrpg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagXJAQ4k1KQUbi6tZO_Ei4oLZQLUjAhaK9WX4FqqLssrvt7-9M4kTdCtE9btYrOzOe-Wbs-YaQdyICDDetY7UOikmVBGtqBwJJdeuQ3kWWWDv89ZuencovczXPCbd1vlY52sTeUMdFwBz5AahKD-_r-sPyL8OuUXi6mlto3CX3kLoMtdrMzZRjAXXWUsixcKfmB-ANAYMrDAxLsQ9_CR5Mbbmknrn_Bm_pv9DnzUuU17zSySPyMMNJejjI_zG5k7on5MGQi6NDidFTcj7DOy9o5SDMp0sk9GcArteb9xQC4r4dFQUcSDNnA9g_eoZlI4muhhu0iWLDMfBPKZzTRUuPv__8_JGJhl66gAfzNGBxDOYO1s_I6cmnH8czlpsssCCNUSxW3gCIcipoD6LhyB-mZBTIQB6cSM4BINBaVQneVGwd900LZsCX3AkvSl49JzvdoksvCY0AP1wdA28biGqidshXZlzQOgkfQ1UQOb5nGzIDOTbC-GNFJiodxWNRPDaLpyD707DlQMFx24AjFOL0Y2TQ7r9YrH7ZvCEtl06qBqlyeCuDFt75ANYOAJ2D-RpdkOa6CthNn0Bph24ntrplAnujvthsEnDIqMAFeTs9hs2MJzSuS6ABFvAorwx8eEFeDOo1raKqNEB5DhMzW4q3tcztJ93Z754wHIKCRpTl7v-n9Yrcx0UM-aU9srNZXaTXgLg2_k2_ra4Aii8kUg
  priority: 102
  providerName: ProQuest
– databaseName: Taylor & Francis Open Access Journals
  dbid: 0YH
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwELWgXJAQ4ruhBRmJa4qd2E7SGxSqBQm4UAQna-zYULXKVrsLv5-Z2Im6FagH9pZNLNmZsefNZOYNYy9ljzC8iVC2xutS6SDLrgUUSGgjEL2Lqqh2-OMnszhRH77pKZtwndMqyYeOiShiPKtpc4NbTxlxr9CkIZDW5N1V8gAtGpohfZPdQkssqImB-L6Ywyyo0UZJNdXu_Gv0llUayfuvUJf-DYBezaO8ZJiO77G7GVHy10kF7rMbYXjA7qRwHE9VRg_Z2YLSXuigQ0-fXxCnf4n4er055OgTjx2pOEJBnmkb8Ajkp1Q5EvgqJdEGTj3H0EQFf8aXkR99_vr-bSk7_hs8fZvnnupjKHywfsROjt99OVqUuc9C6VXT6LKvXYM4CrQ3DqUjiEJMq14SCbkHGQAQExij64Bvqo8gXBfxJHCVAOlkJerHbGdYDmGX8R4RCLS9F7FDx6Y3QJRlDXhjgnS9rwumpvdsfSYhp14Y51ZmrtJJPJbEY7N4CnYwD7tILBzXDXhDQpwfJhLt8Y_l6ofNe9IKBUp3xJYjovJGOnAeVQgxHeB8G1Ow7rIK2M0YQ4mp4Ymtr5nA_qQvNp8KNKQbXdS2LdiL-TbuZ_pIA0NADbAISUXd4E8U7ElSr3kVdW0QzQucWLOleFvL3L4znP4cOcPRL-hkVT39jyXtsdt0meJP-2xns_oVniEi27jn4577A4fIKW0
  priority: 102
  providerName: Taylor & Francis
Title Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
URI https://www.tandfonline.com/doi/abs/10.1080/22221751.2021.1902245
https://www.ncbi.nlm.nih.gov/pubmed/33691606
https://www.proquest.com/docview/3190428788
https://www.proquest.com/docview/2500377770
https://pubmed.ncbi.nlm.nih.gov/PMC8009122
https://doaj.org/article/04a45915640f4c61babc730617a66e76
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED_t4wUJIb7pGJWReE2xE38kSAixsakgbSBEUXmyHMeBaVO6tQXBf89d4lTrNLQX-tCHppZs3_nudxff7wBeiAphuKldkmuvEqmCSIrcoUBCXjuid5Ep1Q4fHevxRH6YqukG9IQKcQMX14Z21E9qMj8b_b748wYP_Ot4Q-4lujgE1oqivVSM0MOhW1KbsI3OyVBTg6OI-FvjbNAHC9nX8vxr9JqXasn8r1CZXgdIr96rvOSoDu_CnYgw2dtOJe7BRmjuw-0uPce6qqMHcDqmazBk-DDyZ-fE8Z8g3l4sXzGMkdsOVQyhIYs0DmgS2QlVkgQ27y7VBkY9yNBlBX_KZjXb__j1_btEFOyX8_Sunnmql6F0wuIhTA4PvuyPk9h3IfHSGJVUWWkQVznldYnS4kQppmQliJTcOxGcQ4ygtcoC7lRVO14WNVqGMuVOlCLl2SPYamZNeAKsQkTi8srzusBAp9KOKMyM81oHUVY-G4Ds99n6SEpOvTHOrIjcpb14LInHRvEMYLQadt6xctw0YI-EuPozkWq3P8zm3208o5ZLJ1VB7Dm8ll6L0pUeDSBiPIfzNXoAxWUVsMs2p1J3DVBsdsMEdnt9sb2S45CiDVnzfADPV4_xfNNLG9cE1ACLEJVnBj98AI879VqtIss0onuOEzNrire2zPUnzcmPlkMc44RCpOnO_9iXp3CLltolpnZhazn_GZ4hVFuWQ9jk38b4baZmCNt7B8efPg_btMewPZZ_AYZxOJo
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VcgAJId4EChgJjmntxHYSJISgpdqlDy4t2pvrOA6tWiXL7hbEn-I3MpOXuhWip-a4WUd2ZjzzzcTzDcAbUSAMT0obptqpUCovwiy1KBCflpboXWREtcN7-3p0KL9M1GQF_vS1MHSssreJjaEuakc58g1UlQbep-mH6Y-QukbR19W-hUarFjv-9y8M2ebvx1so37dRtP35YHMUdl0FQieTRIVFnCeIGqxyOse5cCLMUrIQRLntrPDWogfUWsU-kqooLc-zEvU-j7gVuYh4jM-9ATfR8XIK9pJJMuR0cPtoKWRfKJTyDfS-iPkVBaKRWMcloMdUSy6w6RRwiSf1X2j38qHNC15w-x7c7eAr-9jq231Y8dUDuNPm_lhb0vQQTkd0xoasan0-Z1NqIBAimJ8v3jEMwJv2VwxxJ-s4ItDeshMqU_Fs1p7Y9YwanKE_9O6U1SXb_PptvBWKjP20jg4CMEfFOJSrmD-Cw2t5_Y9htaor_xRYgXDHpoXjZYZRVKEt8aMl1mntRV64OADZv2fjOsZzarxxZkRHjNqLx5B4TCeeANaHYdOW8uOqAZ9IiMOfibG7-aGefTedATBcWqkyoubhpXRa5DZ3aF0RQFqcb6IDyC6qgFk0CZuy7a5i4ismsNbri-lMEA3pN0wAr4fbaDzoi5CtPGqAQfzL4wQvHsCTVr2GVcSxxtCB48SSJcVbWubynerkuCEoxyAkE1H07P_TegW3Rgd7u2Z3vL_zHG7Tgtrc1hqsLmbn_gWivUX-stliDI6ue0__BTCiXvE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NISEkhPgmMMBI8JhhJ7aTIPEAK1XLYPDA0HgyjmPDNJRWbQfiz-I_5C5fWifQHtD6WNeRnTvf_c69-x3AE1EhDM-CjXPtVCyVF3GRWxSIz4MleheZUO3wuz092ZdvDtTBBvzua2EorZJi6NASRTS2mg73vAp9RtwzdGkIpBVFd4nYRo-GbqjPq9z1v35i1LZ8MR2hiJ8myfj1x51J3DUWiJ3MMhVXaZkhcLDK6RKXw4kzS8lKEOu2s8Jbi05Qa5V6fHAVLC-LgKpfJtyKUiQ8xedegIsKfT11i-CfJ8O1Dp4gLYXsa4X-tdo1L9g0CzhFlfo3wHs6b_OEIxxfg6sdgmUvW5W7Dhu-vgFX2us_1lY13YSjCaXZkGGdHS_ZnHoIxIjnl6vnDGPwpgMWQ-jJOpoINLnskCpVPFu0SbueUY8zdIneHbFZYDvvP01HsSjYD-soF4A5qseh64rlLdg_l9d_GzbrWe3vAqsQ8di8cjwUGEhV2hJFWmad1l6UlUsjkP17Nq4jPafeG9-N6LhRe_EYEo_pxBPB9jBt3rJ-nDXhFQlx-DGRdjdfzBZfTWcDDJdWqoLYeXiQTovSlg4NLGJIi-vNdATFSRUwq-bOJrQNVkx6xgK2en0xnRWiKUUTEud5BI-HYbQf9KeQrT1qgEEIzNMMPzyCO616DbtIU43RA8eFZWuKt7bN9ZH68FvDUY5xSCGS5N5_bOkRXPowGpu3073d-3CZRtqrry3YXC2O_QMEg6vyYXP8GHw57_P-B9oAY-I
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heterologous+prime-boost%3A+breaking+the+protective+immune+response+bottleneck+of+COVID-19+vaccine+candidates&rft.jtitle=Emerging+microbes+%26+infections&rft.au=Qian+He&rft.au=Qunying+Mao&rft.au=Chaoqiang+An&rft.au=Jialu+Zhang&rft.date=2021&rft.pub=Taylor+%26+Francis+Group&rft.eissn=2222-1751&rft.volume=10&rft.issue=1&rft.spage=629&rft.epage=637&rft_id=info:doi/10.1080%2F22221751.2021.1902245&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_04a45915640f4c61babc730617a66e76
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2222-1751&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2222-1751&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2222-1751&client=summon